Temferon™
Temferon™
Temferon¹ represents the leading therapeutic platform within Genenta Science’s biotechnology portfolio. The platform embodies a convergence of advanced cellular engineering, gene transfer technologies, and a deep mechanistic understanding of tumor immunology. Its core innovation lies in the use of gene-modified HSPCs as biological delivery systems capable of homing to pathological microenvironments, expressing therapeutic genes in a spatially and temporally controlled manner, and modulating the local immune landscape in a durable and targeted fashion.
The platform's agnostic design — applicable across solid tumor types characterized by TEM infiltration — positions Temferon as a potentially broadly deployable technology, with the capacity to be expanded to additional therapeutic payloads and indications as the clinical and preclinical evidence base continues to mature.
1: Temferon™ is an investigational product candidate. Its safety and efficacy have not been established. It is not approved for use in any jurisdiction. Clinical data presented are preliminary and subject to adjustment pending final clinical site and regulatory review.
1: Temferon™ is an investigational product candidate. Its safety and efficacy have not been established. It is not approved for use in any jurisdiction. Clinical data presented are preliminary and subject to adjustment pending final clinical site and regulatory review.